AU2015204192B2 - Dosage regimen of ferric trimaltol - Google Patents

Dosage regimen of ferric trimaltol Download PDF

Info

Publication number
AU2015204192B2
AU2015204192B2 AU2015204192A AU2015204192A AU2015204192B2 AU 2015204192 B2 AU2015204192 B2 AU 2015204192B2 AU 2015204192 A AU2015204192 A AU 2015204192A AU 2015204192 A AU2015204192 A AU 2015204192A AU 2015204192 B2 AU2015204192 B2 AU 2015204192B2
Authority
AU
Australia
Prior art keywords
ferric trimaltol
iron
iron deficiency
anaemia
ferric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
AU2015204192A
Other languages
English (en)
Other versions
AU2015204192A1 (en
Inventor
Julian David HOWELL
Christian Schweiger
Carl Andrew STERRITT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shield Tx UK Ltd
Original Assignee
Shield Tx UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201400171A external-priority patent/GB201400171D0/en
Priority claimed from GB201418708A external-priority patent/GB201418708D0/en
Application filed by Shield Tx UK Ltd filed Critical Shield Tx UK Ltd
Publication of AU2015204192A1 publication Critical patent/AU2015204192A1/en
Application granted granted Critical
Publication of AU2015204192B2 publication Critical patent/AU2015204192B2/en
Assigned to Shield TX (UK) Limited reassignment Shield TX (UK) Limited Request for Assignment Assignors: IRON THERAPEUTICS HOLDINGS AG
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2015204192A 2014-01-06 2015-01-06 Dosage regimen of ferric trimaltol Active 2036-03-02 AU2015204192B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB201400171A GB201400171D0 (en) 2014-01-06 2014-01-06 Dosage regimen
GB1400171.3 2014-01-06
GB201418708A GB201418708D0 (en) 2014-10-21 2014-10-21 Dosage regimen
GB1418708.2 2014-10-21
PCT/IB2015/050098 WO2015101971A1 (en) 2014-01-06 2015-01-06 Dosage regimen of ferric trimaltol

Publications (2)

Publication Number Publication Date
AU2015204192A1 AU2015204192A1 (en) 2016-07-07
AU2015204192B2 true AU2015204192B2 (en) 2020-03-26

Family

ID=52432872

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015204192A Active 2036-03-02 AU2015204192B2 (en) 2014-01-06 2015-01-06 Dosage regimen of ferric trimaltol

Country Status (12)

Country Link
US (1) US10179120B2 (enExample)
EP (1) EP3091974B1 (enExample)
JP (2) JP6556753B2 (enExample)
KR (1) KR102351422B1 (enExample)
CN (2) CN114010629A (enExample)
AU (1) AU2015204192B2 (enExample)
BR (1) BR112016015766A2 (enExample)
CA (1) CA2934836C (enExample)
ES (1) ES2785391T3 (enExample)
IL (1) IL246613B (enExample)
SI (1) SI3091974T1 (enExample)
WO (1) WO2015101971A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102351422B1 (ko) 2014-01-06 2022-01-13 실드 티엑스 (유케이) 리미티드 철 트리말톨의 복용량 양생법
GB201418710D0 (en) 2014-10-21 2014-12-03 Iron Therapeutics Holdings Ag Dosage regimen
CN109071481B (zh) 2016-03-31 2022-09-30 英国神盾Tx股份有限公司 用于由元素铁产生麦芽酚铁组合物的方法
EP3436442B1 (en) 2016-03-31 2020-10-28 Shield TX (UK) Limited Methods for producing ferric maltol compositions from ferrous hydroxides
US11267836B2 (en) 2016-03-31 2022-03-08 Shield TX (UK) Limited Methods for producing ferric maltol compositions from ligand modified and ligand coated ferric hydroxides
AU2017242908B2 (en) * 2016-03-31 2022-11-17 Shield TX (UK) Limited Ferric maltol compositions for use in the treatment or prevention of cancer and tumours
GB2553099A (en) * 2016-08-19 2018-02-28 Shield Tx Uk Ltd Use
IT202100018578A1 (it) * 2021-07-14 2023-01-14 Indena Spa Dispersione amorfa di maltolo ferrico e relativo processo di preparazione
WO2026017901A1 (en) 2024-07-18 2026-01-22 Malian Biologicals Gmbh Iron supplementation in neurodevelopmental or psychiatric disorder

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1150213B (it) 1982-03-02 1986-12-10 Italfarmaco Spa Derivati di ferro biodisponibile esenti da gastrolesivita',procentimento di preparazione e relative composizioni farmaceutiche
SU1676626A1 (ru) * 1989-05-17 1991-09-15 Тюменский государственный медицинский институт Способ лечени железодефицитных анемий
RO113611B1 (ro) 1990-08-03 1998-09-30 Asta Pharma Ag Preparate solide de ifosfamida, administrate oral si procedeu de obtinere
ATE273702T1 (de) 1995-06-10 2004-09-15 Vitra Pharmaceuticals Ltd Eisenverbindungen, zusammensetzungen, herstellungsverfahren und verwendungen davon
ID18663A (id) 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
NZ328751A (en) 1997-09-16 1999-01-28 Bernard Charles Sherman Solid medicament containing an anionic surfactant and cyclosporin
ES2236300T3 (es) 2000-09-19 2005-07-16 Vitra Pharmaceuticals Ltd. Composiciones de hierro.
US20050118291A1 (en) 2003-09-10 2005-06-02 Mian-Ying Wang Formulations and methods for treating breast cancer with Morinda citrifolia and methylsulfonymethane
MX2007013708A (es) 2005-05-03 2008-01-28 Innozen Inc Pelicula comestible para suministro transmucosa de complementos nutricionales.
EP1757299A1 (de) * 2005-08-25 2007-02-28 Vifor (International) Ag Eisen(III)-Komplexverbindungen zur Behandlung von Eisenmangel-Zuständen bei Patienten mit chronisch-entzündlicher Darmerkrankung
US20070111936A1 (en) 2005-11-15 2007-05-17 Vladimir Pak Complex of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer
GB0808835D0 (en) * 2008-05-15 2008-06-18 Vitra Pharmaceuticals Ltd Therapeutic compositions
GB201101370D0 (en) 2011-01-27 2011-03-09 Iron Therapeutics Holdings Ag Process
JP5856725B2 (ja) 2011-08-02 2016-02-10 和夫 酒井 うつ病治療用または予防用医薬組成物
KR102351422B1 (ko) 2014-01-06 2022-01-13 실드 티엑스 (유케이) 리미티드 철 트리말톨의 복용량 양생법
GB201418710D0 (en) 2014-10-21 2014-12-03 Iron Therapeutics Holdings Ag Dosage regimen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REFFITT, DAVID M. et al, "Assessment of iron absorption from ferric trimaltol", ANNALS OF CLINICAL BIOCHEMISTRY, 2000, vol. 37, no. 4, pages 457 - 466 *

Also Published As

Publication number Publication date
ES2785391T3 (es) 2020-10-06
CA2934836A1 (en) 2015-07-09
AU2015204192A1 (en) 2016-07-07
CN114010629A (zh) 2022-02-08
KR20160105499A (ko) 2016-09-06
JP6556753B2 (ja) 2019-08-07
EP3091974B1 (en) 2020-04-01
JP2017501235A (ja) 2017-01-12
CN106413706A (zh) 2017-02-15
SI3091974T1 (sl) 2020-08-31
WO2015101971A1 (en) 2015-07-09
CA2934836C (en) 2022-03-22
JP2019131592A (ja) 2019-08-08
IL246613A0 (en) 2016-08-31
US10179120B2 (en) 2019-01-15
BR112016015766A2 (pt) 2017-08-08
EP3091974A1 (en) 2016-11-16
US20160324822A1 (en) 2016-11-10
IL246613B (en) 2020-05-31
KR102351422B1 (ko) 2022-01-13

Similar Documents

Publication Publication Date Title
AU2015204192B2 (en) Dosage regimen of ferric trimaltol
KR960016582B1 (ko) 위장장해의 치료 및 예방용 약제학적 조성물
JP2022070945A (ja) 慢性腎臓病患者の治療におけるクエン酸第二鉄の使用
US20140221434A1 (en) Altering pharmacokinetics of pirfenidone therapy
JP6828100B2 (ja) 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄
KR960011772B1 (ko) 개선된 디데옥시 퓨린 뉴클레오사이드 경구 투여 제제
EP2316453B1 (en) Reduction of dizziness, a side effect associated with pirfenidone therapy
CA2965096C (en) Dosage regiment of ferric maltol
RU2541092C2 (ru) Бисглицинат-хелат железа для использования в пероральном лечении анемии у пациентов с целиакией
KR20160118234A (ko) 만성 신장병의 진행 억제 또는 개선제
HK40065667A (zh) 三麦芽酚铁的剂量方案
CN117138047B (zh) Tlr4抑制剂在制备缓解索拉非尼所致胃肠道毒性的药物中的应用
TW202547454A (zh) 治療前的尿白蛋白濃度在特定範圍之慢性腎臟病的治療用醫藥組成物
KR20060011615A (ko) 생체이용율이 증진된 알렌드론산 제제
Yimam et al. Gastrointestinal and Metabolic Disorders and Drugs
HK1151726B (en) Reduction of dizziness, a side effect associated with pirfenidone therapy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: SHIELD TX (UK) LIMITED

Free format text: FORMER OWNER(S): IRON THERAPEUTICS HOLDINGS AG

NC Extension of term for standard patent requested (sect. 70)

Free format text: PRODUCT NAME: FERACCRU FERRIC MALTOL

Filing date: 20210302

NDA Extension of term for standard patent accepted (sect.70)

Free format text: PRODUCT NAME: FERACCRU FERRIC MALTOL

Filing date: 20210302

NDB Extension of term for standard patent granted (sect.76)

Free format text: PRODUCT NAME: FERACCRU FERRIC MALTOL

Filing date: 20210302

Extension date: 20360302